Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015)
- PMID: 27646439
- DOI: 10.1080/13543776.2017.1238072
Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015)
Abstract
PKR-like endoplasmic reticulum kinase (PERK) is an essential component of the unfolded protein response (UPR) and a critical regulator of protein synthesis during endoplasmic reticulum (ER) stress. Transient PERK activation is protective; however, chronic ER stress and sustained PERK activation can be detrimental to cell health. Many diseases are associated with PERK over-activation, suggestive that small molecule PERK inhibitors may provide new opportunities for treating cancer and neurodegenerative diseases, among others. Areas covered: This review covers the therapeutic potential of PERK modulation and will focus more specifically on small molecule inhibitors of PERK disclosed in the patent literature from 2010-2015. During this time period the first PERK inhibitor patents appeared disclosing novel, potent, and selective inhibitors of PERK. Expert opinion: Compelling preclinical and clinical evidence supports the potential use of PERK modulators for a variety of diseases, particularly cancer and neurodegenerative disease. Potent and selective PERK inhibitors have been characterized pharmacologically and are available for further study. Despite high therapeutic potential, the future clinical use of PERK inhibitors will require thorough safety and toxicity evaluation to gauge therapeutic index and develop a framework for risk-benefit assessment.
Keywords: Cancer; ER stress; PERK; kinase; neurodegeneration; protein synthesis; unfolded protein response.
Similar articles
-
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases.Int J Mol Sci. 2020 Mar 19;21(6):2108. doi: 10.3390/ijms21062108. Int J Mol Sci. 2020. PMID: 32204380 Free PMC article. Review.
-
[Potential therapeutic application of PERK inhibitors].Postepy Biochem. 2019 Jun 6;65(2):118-127. doi: 10.18388/pb.2019_262. Postepy Biochem. 2019. PMID: 31642650 Review. Polish.
-
Protein-rich foods, sea foods, and gut microbiota amplify immune responses in chronic diseases and cancers - Targeting PERK as a novel therapeutic strategy for chronic inflammatory diseases, neurodegenerative disorders, and cancer.Pharmacol Ther. 2024 Mar;255:108604. doi: 10.1016/j.pharmthera.2024.108604. Epub 2024 Feb 13. Pharmacol Ther. 2024. PMID: 38360205 Free PMC article. Review.
-
The unfolded protein response in neurodegenerative disorders - therapeutic modulation of the PERK pathway.FEBS J. 2019 Jan;286(2):342-355. doi: 10.1111/febs.14422. Epub 2018 Mar 11. FEBS J. 2019. PMID: 29476642 Review.
-
Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy.Hepatol Int. 2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0. eCollection 2015 Jan. Hepatol Int. 2014. PMID: 25598862 Free PMC article.
Cited by
-
Endoplasmic reticulum proteostasis impairment in aging.Aging Cell. 2017 Aug;16(4):615-623. doi: 10.1111/acel.12599. Epub 2017 Apr 23. Aging Cell. 2017. PMID: 28436203 Free PMC article. Review.
-
Endoplasmic Reticulum Stress, a Driver or an Innocent Bystander in Endothelial Dysfunction Associated with Hypertension?Curr Hypertens Rep. 2017 Aug;19(8):64. doi: 10.1007/s11906-017-0762-x. Curr Hypertens Rep. 2017. PMID: 28717886 Review.
-
The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2α in Neurodegeneration.J Neuropathol Exp Neurol. 2020 Feb 1;79(2):123-143. doi: 10.1093/jnen/nlz129. J Neuropathol Exp Neurol. 2020. PMID: 31913484 Free PMC article. Review.
-
The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress.J Biol Chem. 2019 May 17;294(20):8197-8217. doi: 10.1074/jbc.RA118.002829. Epub 2019 Mar 29. J Biol Chem. 2019. PMID: 30926605 Free PMC article.
-
The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.Front Pharmacol. 2022 Jul 15;13:853568. doi: 10.3389/fphar.2022.853568. eCollection 2022. Front Pharmacol. 2022. PMID: 35910347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
